Aslan Licenses Array Cancer Drug

Aslan Pharmaceuticals and Array BioPharma have entered into a license agreement to develop Array’s HER2/EGFR inhibitor, ARRY-543, currently in Phase II development for solid tumors.
Aslan will fund development through proof-of-concept, targeting gastric cancer in a development program conducted in Asia. Aslan will then find a global partner for Phase III development and commercialization and will share a portion of the proceeds. The agreement also includes an option for the two parties to negotiate to license a second undisclosed compound.

“Our partnership with Aslan provides a great opportunity to fund and advance the development of ARRY-543,” said Robert E. Conway, chief executive officer of Array BioPharma. “Aslan’s creative development strategy of leveraging Asia to conduct clinical development is particularly compelling for ARRY-543 due to the high prevalence of patients with gastric cancer in Asia. Aslan’s oncology team, led by Dr. Alan Barge, provides a rare combination of global and Asian drug development experience.”